AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer

Mark A. Socinski,¹ Alex Spira,² Luis Paz-Ares,³ Martin Reck,⁴ Shun Lu.⁵ Makoto Nishio,⁶ Jiang Li,⁷ Yunfei Zhou,⁷ Sandra Chica-Dugue,⁷ Joon Whan Rhee,⁷ Xinmin Yu⁸

¹AdventiHealth Cancer Institute, Orlando, FL, USA; ²Virginia Cancer Specialists, US Oncology Research & The US Oncology Network, New York University, Fairfax, VA, USA; ³Department of Medical Oncology, Hospital Universitation 12 De Octubre, Madrid, Spain; ⁴Lung Clinic Grosshansdorf, Airway Research & The US Oncology, Research & The US Oncology, Research & Grosshansdorf, Airway Research & Grosshansdorf, Airway Research & Grosshansdorf, Airway Research & Grosshansdorf, Airway Research & Grosshansdorf, Germany; ⁴Shanghai Chest Hospital, Shanghai, China; ⁴Department of Medical Oncology, Cancer Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; ⁷BeiGene (US) Co., Ltd., NJ, USA; ⁴Department of Medical Oncology, Cancer Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; ⁷BeiGene (US) Co., Ltd., NJ, USA; ⁴Department of Medical Oncology, Cancer Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; ⁷BeiGene (US) Co., Ltd., NJ, USA; ⁴Department of Medical Oncology, Cancer Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; ⁷BeiGene (US) Co., Ltd., NJ, USA; ⁴Department of Medical Oncology, Cancer Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; ⁷BeiGene (US) Co., Ltd., NJ, USA; ⁴Department of Medical Oncology, Cancer Hospital, Hangzhou, China

Poster No. TPS9128

Introduction


Unmet need in lung cancer

- Lung cancer is the most common cancer worldwide (2.2 million cases in 2020) and the leading cause of cancer mortality worldwide (1.8 million deaths in 2020)¹
- Non-small cell lung cancers (NSCLC) represent ~85% of lung cancer cases, and long-term prognosis with conventional treatment is poor for
 patients with locally advanced or metastatic disease^{2,3}
- In Monotherapy with programmed death 1 (PD-1)/programmed death ligand 1 (PD-1) monoclonal antibodies (mAbs) has improved clinical outcomes for patients with non-oncogenic driven NSCLC, but clinical efficacy is limited by primary and secondary resistance, and improvements in overall survival (OS) are required^{4,5}

Introduction to ociperlimab, tislelizumab and the AdvanTIG-302 study

- T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is a co-inhibitory, immune checkpoint receptor that is upregulated on T cells and natural killer cells in multiple solid tumors, which can inhibit anticancer immune responses²
- Ociperlimab (BGB-A1217) is a novel, humanized mAb that binds to TIGIT with high affinity and specificity, blocking the interaction with its ligands on tumor cells, and has competent Fc effector function⁶ (Figure 1)⁹
- Tislelizumab is an anti-PD-1 mAb that has been engineered to minimize binding to FcyR on macrophages and abrogate antibody-dependent phagocytosis, which has been proposed as a potential mechanism of resistance to established anti-PD-1 mAbs^{10,11}
- Dual targeting of tumors with anti-TIGIT and anti-PD-1 mAbs produces synergistic immune cell activation and enhanced antitumor activity in preclinical and clinical studies^{8,12}
- We report the design of the ongoing Phase 3 AdvanTiG-302 study, which is investigating the efficacy and safety of ocipertimab plus tistelizumab vs the anti-PD-1 mAb pembrolizumab as a single agent, in patients with PD-L1-selected, previously untreated, locally advanced, unresectable or metastatic NSCLC

Figure 1. Ociperlimab activates T/NK cells by blocking TIGIT and ligand interaction



Methods

Study design


- AdvanTIG-302 is a Phase 3, multicenter, international, randomized, double-blind study currently being conducted in 170 centers (clinicaltrials.gov NCT04746924) (Figure 2)
- Approximately 605 adults with PD-L1-selected, locally advanced or recurrent NSCLC that is unresectable or not amenable to radiotherapy, with or without chemoradiotherapy, or previously untreated metastatic disease, whose turnes do not harbor epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) transicotions will be enrolled (Figure 3)
- Study enrollment has begun and is ongoing
- Eligible patients will be randomized 5:5:1 to:
- Arm A: Ociperlimab 900 mg plus tislelizumab 200 mg intravenously (IV) every 3 weeks (Q3W)
- Arm B: Pembrolizumab 200 mg plus placebo IV Q3W
- Arm C: Tislelizumab 200 mg plus placebo IV Q3W
- Stratification factors include histology (squamous vs non-squamous) and region (Asia vs non-Asia)
- Study treatments will be confined until disease progression by Response Evaluation Criteria in Solid Tumors version 1.1 (RESCITV.1.), unacceptable toxido), withdrawa, or the timepoint at which the investigator considers that the patient is no longer benefiting from study treatment. Treatment beyond investigator-assessed, RECIST v1.1-defined disease progression is permitted. Crossover between treatments is not permitted
- Tisleizumab monotherapy has demonstrated activity in pre-treated NSCLC and is expected to be active in patients with previously untreated NSCLC. Am C was implemented with the intent to generate tisleizumab monotherapy data in this specific NSCLC population so that the relative contributions of tisleizumab and objectime in Am A can be understood

Conclusions

AdvanTIG-302 is an ongoing Phase 3 study investigating whether ociperlimab + tislelizumab combination therapy prolongs PFS and OS vs pembrolizumab monotherapy in adults with PD-11 high, locally advanced/recurrent or untreated metastatic NSCLC

This study will provide insight into the effect of dual targeting with anti-TIGIT and anti-PD-1 antibodies (ociperlimab and tiselizumab) vs anti-PD-1 monotherapy (pembrolizumab) in first-line NSCLC





Radomization statisfied by histology (regularities) is non-paulity and region (Alais is non-Alai). "Patients were heighter if twy fast after the betweeninged losses as a subminure disease or infection in history of interstitties (gealesse or absents) and earlier material statistical and the registral statistical interaction and strengt and supplied processing of the values is 2 and on analysing 2 and participation in chical field, or a pregular woman. The timepoint al which the investigator considers that the patient is nonsingle another of the values is 2 and on a strengt and the constraint of the strengt and anyone another than that is retained.

Study population

- Key eligibility criteria included:
- Aged ≥ 18 years
- Histologically or cytologically documented locally advanced or recurrent NSCLC ineligible for curative surgery or definitive radiotherapy (with or without chemoradiotherapy), or metastatic NSCLC (non-squamous or squamous)
- No prior systemic treatment for metastatic NSCLC
- Provision of fresh or archival tumor tissue for central evaluation of levels of PD-L1 and other biomarkers
- Tumor cell PD-L1 expression ≥ 50% (centrally determined by VENTANA PD-L1 [SP263] assay)
- ≥ 1 measurable lesion, as per RECIST v1.1
- ECOG PS (Eastern Cooperative Oncology Group performance status) ≤ 1
- Adequate organ function
- No known sensitizing mutation in the EGFR gene or ALK fusion oncogene
- No prior treatment with anti-PD-1/L1 antibodies or any other checkpoint inhibitors

Endpoints and assessments

- Dual primary endpoints are:
 - Investigator-assessed progression-free survival (PFS) according to RECIST v1.1 for Arm A vs B
 OS for Arm A vs B
- Secondary endpoints and exploratory endpoints are listed in Table 1
- All efficacy-related endpoints will be assessed in the intent-to-treat analysis set (all randomized patients)
- Radiological imaging will be performed every 9 weeks for the first year of the study and every 12 weeks thereafter
- Tumor responses will be assessed by investigators and a blinded independent review committee (BIRC) using RECIST v1.1
- Patient-reported health-related quality of life assessments will be performed at baseline, every other cycle through Cycle 13, every 4 cycles thereafter, and at the end-of-treatment visit
- Safety will be assessed through monitoring of the incidence and severity of adverse events (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0), laboratory results, vital signs, ECOG PS, and other examinations
- Safety analyses will be performed using the safety analysis set (all randomized patients receiving ≥ 1 dose of study drug)

Statistical analysis

- The dual primary endpoints of PFS and OS will be estimated using the Kaplan-Meier method, with a stratified log-rank test used to compare Arm A vs B and treatment effect estimated using a Cox regression model
- Two interim analyses are planned:
- An interim analysis will be performed for PFS when ~65% of the targeted number of anticipated events have occurred;
- An interim analysis will be performed for OS at the time of final PFS analysis

Table 1. Secondary and exploratory endpoints

Secondary endpoints	Exploratory endpoints
PFS by BIRC* in Arm A and Arm B	ORR and DoR by BIRC* in Arm A and Arm B
ORR by investigators* in Arm A and Arm B	DCR, CBR and TTR by BIRC and investigators* in Arm A and Arm B
DoR by investigators* in Arm A and Arm B	PFS after next line of treatment (PFS2)
Health-related quality of life	OS, PFS, ORR, DoR, by BIRC and investigators* in Arm C
EORTC QLQ-C30 ⁺ EORTC QLQ-C13	Incidence and severity of AEs in Arm C
EQ-5D-5L questionnaire	 Association between biomarkers and response or resistance
Time to deterioration	Pharmacokinetics
Incidence and severity of AEs	Host immunogenicity

*According to RECIST v1.1; *Analyzed using the global health status scale of the QLQ-C30 tool

AE softwist events BHC binder independer meier committer CBR, clinical alread metro CBR, disease conton into: DRR duration of approace. EDRTG, Europea Operation for Research and Treatment of Concer, EDRTG (QL-QC), EDRTG (Quality of LRP Questionnaire Core 8), EDRTG QL-QL-D1, EDRTG (CL), Quality of LR Questionniae Lung Cuerce 11, EOSD-82, 51 evel EuroPd 5 Dimension, ORR overall response table, S0, overall survival, FPS, progression-feer and vision andmatiscular to decide diseases on Bern and in on the Element or dealth from any cuase, whicher occurs fast TTR, THE or propose

References

1. Bray F, et al. CA Cancer Clin J. 2018;68:394-42
2. Tun AM, et al. Future Sci OA 2019;5:FSO421
3. Hansen RN, et al. BMC Cancer 2020;20:276
4. Santini FC, Hellmann MD. Cancer J 2018;24:15-
5. Sui H, et al. J Immunol Res 2018;2018:6984948
6. Manieri NA, et al. Trends Immunol 2017;38:20-8

Harjunpää H, Guillerey C. Clin Exp Immunol 2020;200:108–19
 Chen X, et al. Presented at AACR
 Johnston RJ, et al. Cancer Cell 2014;26:823–37
 Clin S, et al. Future Oncol 2019;15:1811–2018;67:1079–90
 Z. Rodriguez-Ahreu D, et al. J Clin Oncol 2020;38:9503

Acknowledgements

This study is sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Louise Oakes, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by BeiGene, Ltd.

Author contact details: Mark.Socinski.MD@AdventHealth.com (Mark A. Socinski